Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerry Avorn

Showing results (91-100 of 436) with videos related to

Pageof 44
Sort By:
BMJ (Clinical Research Ed.)|October 9, 2020
Accounting for US public funding in drug development: how can we better balance access, affordability, and innovation?Ameet Sarpatwari, Jerry Avorn, Aaron S Kesselheim
JAMA Internal Medicine|March 28, 2017
Medicaid Expenditures and Estimated Rebates for Epinephrine Autoinjectors, 2012 to 2016Jing Luo, Aaron S Kesselheim, Jerry Avorn
Journal of the American Geriatrics Society|February 12, 2009
Pharmacological management of osteoporosis in nursing home populations: a systematic reviewSeema Parikh, Jerry Avorn, Daniel H Solomon
Circulation. Cardiovascular Quality and Outcomes|October 25, 2012
Origins of medical innovation: the case of coronary artery stentsShuai Xu, Jerry Avorn, Aaron S Kesselheim
The New England Journal of Medicine|October 26, 2017
The Price of Crossing the Border for MedicationsMichael Fralick, Jerry Avorn, Aaron S Kesselheim
Pharmacoepidemiology and Drug Safety|February 18, 2010
Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databasesJeremy A Rassen, Jerry Avorn, Sebastian Schneeweiss
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 25, 2002
Chronic kidney disease as a risk factor for bleeding complications after coronary artery bypass surgeryWolfgang C Winkelmayer, Raisa Levin, Jerry Avorn
Pain Physician|February 23, 2017
Educational Outreach to Opioid Prescribers: The Case for Academic DetailingMargot Trotter Davis, Brian Bateman, Jerry Avorn
The New England Journal of Medicine|March 28, 2008
Drug-review deadlines and safety problemsDaniel Carpenter, Evan James Zucker, Jerry Avorn
The New England Journal of Medicine|June 16, 2016
State Initiatives to Control Medication Costs--Can Transparency Legislation Help?Ameet Sarpatwari, Jerry Avorn, Aaron S Kesselheim
Pageof 44

Showing results (91-100 of 436) with videos related to

Sort By:
Pageof 44
BMJ (Clinical Research Ed.)|October 9, 2020
Accounting for US public funding in drug development: how can we better balance access, affordability, and innovation?Ameet Sarpatwari, Jerry Avorn, Aaron S Kesselheim
JAMA Internal Medicine|March 28, 2017
Medicaid Expenditures and Estimated Rebates for Epinephrine Autoinjectors, 2012 to 2016Jing Luo, Aaron S Kesselheim, Jerry Avorn
Journal of the American Geriatrics Society|February 12, 2009
Pharmacological management of osteoporosis in nursing home populations: a systematic reviewSeema Parikh, Jerry Avorn, Daniel H Solomon
Circulation. Cardiovascular Quality and Outcomes|October 25, 2012
Origins of medical innovation: the case of coronary artery stentsShuai Xu, Jerry Avorn, Aaron S Kesselheim
The New England Journal of Medicine|October 26, 2017
The Price of Crossing the Border for MedicationsMichael Fralick, Jerry Avorn, Aaron S Kesselheim
Pharmacoepidemiology and Drug Safety|February 18, 2010
Multivariate-adjusted pharmacoepidemiologic analyses of confidential information pooled from multiple health care utilization databasesJeremy A Rassen, Jerry Avorn, Sebastian Schneeweiss
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 25, 2002
Chronic kidney disease as a risk factor for bleeding complications after coronary artery bypass surgeryWolfgang C Winkelmayer, Raisa Levin, Jerry Avorn
Pain Physician|February 23, 2017
Educational Outreach to Opioid Prescribers: The Case for Academic DetailingMargot Trotter Davis, Brian Bateman, Jerry Avorn
The New England Journal of Medicine|March 28, 2008
Drug-review deadlines and safety problemsDaniel Carpenter, Evan James Zucker, Jerry Avorn
The New England Journal of Medicine|June 16, 2016
State Initiatives to Control Medication Costs--Can Transparency Legislation Help?Ameet Sarpatwari, Jerry Avorn, Aaron S Kesselheim
Pageof 44